Francisco Hernandez-Ilizaliturri MD

Hematologic Oncology

Director of the Lymphoma Research, Head of the Lymphoma Translational Research Program, Professor of Medical Oncology, Department of Medicine, Roswell Park Cancer Institute. Associate Professor of Medicine, SUNY Buffalo School of Medicine and Biomedical Sciences

Join to view full profile

Elm and Carlton StreetsBuffalo, NY 14263
Phone+1 716-845-2300

Dr. Hernandez-Ilizaliturri is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hernandez-Ilizaliturri's full profile Already have an account?

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 1999 - 2002
University at BuffaloResidency, Internal Medicine, 1996 - 1999
Escuela de Medicina Ignacio A. SantosClass of 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2009 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Sunrise Patient Portal and Sunrise Acute Care EHR, Allscripts, 2014
CMS Meaningful Use Stage 1 Certification Sunrise Patient Portal and Sunrise Acute Care EHR, Allscripts, 2014
CMS Meaningful Use Stage 1 Certification Sunrise Patient Portal and Sunrise Acute Care EHR, Allscripts, 2014

Clinical Trials

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2011 Dec 06
COMPLETED
PHASE2
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma Start of enrollment: 2007 Apr 17
COMPLETED
PHASE2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
ACTIVE_NOT_RECRUITING
PHASE2

Publications & Presentations

PubMed

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.
Lara Stepan, Sahar Ansari, Jeremy S Abramson, Abood Okal, Justine Dell'Aringa
Journal of Clinical Oncology. 2026-07-01
Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.
Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Blood Advances. 2026-05-12
Treatment of older adults with peripheral T cell lymphoma (PTCL) amidst a changing therapeutic landscape: a 20-year single institution experience.
Muhammad Salman Faisal, Andrea Anampa Guzman, Kristopher Attwood, Pallawi Torka, Matthew Cortese
Leukemia & Lymphoma. 2026-03-01

Abstracts/Posters

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Ce...
Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT Era
Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)Clinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-cell Lymphomas? New Insights at ASHDecember 9th, 2024
Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic LeukemiaDecember 7th, 2024
Castle Connolly Names 38 Roswell Park Physicians to ‘Top Doctors’ ListFebruary 2nd, 2023